Our Development Portfolio
We strategically select our portfolio to enable our program management and technical teams to design rapid and risk-mitigated development pathways for each product. This approach allows us to move quickly through or even avoid early-phase studies, and accelerate progress to pivotal clinical assessments and successful submissions. Each of our distinctive, high-quality products delivers enhanced value to patients through our formulation optimization and unique technology applications. Banner Life Sciences™ is rapidly executing a dynamic portfolio of products across diverse therapeutic areas such as pain, oncology, nephrology, and gastroenterology, and our Ideation Advisory Board continues to evaluate future candidates for portfolio addition.
Banner Life Sciences’ fully integrated product-development team of experienced formulators, analytical scientists, clinical affairs and regulatory specialists work to create novel formulations for products that meet patient needs. Historically a softgel company, our product portfolio is expanded and incorporates multiple-dosage platforms and capabilities, including tablets and sterile injectables. Each of our development products is strategically selected with a formulation approach, which applies proprietary technologies to create valuable solutions. Our product-development team is driven by a commitment to both quality and speed, taking products from bench to commercial process validation smoothly and efficiently.